# Atrial Flow Regulator: Bridging Pediatric Patients With Pulmonary Arterial Hypertension to Lung Transplantation

## TL;DR

A new device called an atrial flow regulator helps stabilize pediatric patients with severe pulmonary hypertension before lung transplantation, improving outcomes and allowing for safer surgery.

## Contribution

The study demonstrates the effectiveness of atrial flow regulators as a bridging strategy for pediatric PAH patients awaiting lung transplantation.

## Key findings

- AFR implantation stabilized two pediatric patients with severe PAH, enabling successful listing for lung transplantation.
- Post-transplant percutaneous closure of the AFR fenestration minimized long-term complications.
- AFR use allowed for complete cardiac remodeling in both patients after lung transplantation.

## Abstract

Pulmonary arterial hypertension (PAH) in pediatric patients remains challenging, particularly in symptomatic patients with right heart failure despite optimal medical therapy. The use of an atrial flow regulator (AFR) to decompress the right ventricle has offered a new therapeutic approach for those patients and allows bridging for lung transplantation (LTX). Data on pretransplant decision-making, perioperative considerations, and post-transplant management in pediatric patients undergoing LTX are limited.

We report 2 pediatric patients with severe symptomatic PAH and right heart failure in whom an AFR was implanted before LTX. In both patients, AFR implantation resulted in clinical stabilization, allowing for successful listing and subsequent LTX. After LTX, both patients showed complete cardiac remodeling, and the AFR fenestration was closed percutaneously to minimize long-term complications.

AFR implantation is a valuable bridging strategy to LTX in pediatric patients with therapy-refractory PAH, enabling clinical stabilization and safer perioperative management. Post-transplant transcatheter closure is reasonable to reduce long-term risks associated with persistent atrial shunting.